Background The cardiovascular safety and efficacy of many current antihyperglycemic agents,
including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. Methods We …

Background The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney …

Background— Diabetes mellitus and heart failure frequently coexist. However, few diabetes
mellitus trials have prospectively evaluated and adjudicated heart failure as an end point. …

Importance Among nontraditional cardiovascular risk factors, recent influenzalike infection
is associated with fatal and nonfatal atherothrombotic events. Objectives To determine if …

Despite current established therapy, heart failure (HF) remains a leading cause of hospitalization
and mortality worldwide. Novel therapeutic targets are therefore needed to improve the …

Aims Recent trials have examined the effect of prolonged dual antiplatelet therapy (DAPT)
in a variety of patient populations, with heterogeneous results regarding benefit and safety, …

Background Patients with acute heart failure are frequently or systematically hospitalized,
often because the risk of adverse events is uncertain and the options for rapid follow-up are …

Background Some glucose-lowering drugs or strategies adversely affect cardiovascular
outcomes. We aimed to assess the extent to which glucose lowering by various drugs or …

Context Among adult patients with liver disease, the ability to identify those most likely to have
cirrhosis noninvasively is challenging. Objective To identify simple clinical indicators that …

Background There is concern that antidiabetic incretin-based drugs, including dipeptidyl
peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, can increase …